{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009469","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.857388+00:00","generated_at":"2026-06-17T19:10:52.842232+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAtla reports FY2022 net loss $106.5M, cash $215.5M; advances CAB-ADC and bispecific trials","bullets":["Net loss Q4 2022 $27.5M, full year $106.5M, vs Q4 2021 $23.4M and FY2021 $95.4M.","R&D expenses FY2022 $79.3M, up from $58.3M in FY2021, driven by clinical development.","Cash $215.5M at year-end 2022; expected to fund operations into 2025.","Cleared DLT for BA3011 dose-intensive schedule; LMS readout 2H23; UPS registrational Phase 2 start in 1H23.","FDA cleared IND for BA3182 (CAB-EpCAMxCD3 TCE); FPI Phase 1 in 1H23. BA3021 NSCLC and BA3071 Phase 2 data in 2H23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009469","json":"https://secwatch.observer/filing/0000950170-23-009469.json","markdown":"https://secwatch.observer/filing/0000950170-23-009469.md","text":"https://secwatch.observer/filing/0000950170-23-009469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/0000950170-23-009469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/bcab-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:10:52.842232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53875ec6ad403ba6d148289c3c562a7f01303272","claim":"BioAtla, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023009469/0000950170-23-009469-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}